Why the study?
Does candesartan prevent new microalbuminuria in mostly normotensive patients with type 1 or type 2 diabetes?
Population
5,231 patients who were mostly normotensive and all had normoalbuminuria
Comparison
Candesartan, 16 mg/d increasing to 32 mg/d vs Placebo
Design
RCT, Assignment was done centrally using an interactive voice-response system…
Follow-up
median 4.7 years
Authors
Loading...
Argues against candesartan to prevent microalbuminuria in normotensive diabetes; confirms no benefit in this population.
Does candesartan prevent new microalbuminuria in mostly normotensive patients with type 1 or type 2 diabetes?
Candesartan at 32 mg/d does not significantly prevent the development of microalbuminuria in mostly normotensive patients with type 1 or type 2 diabetes.
Rudy Bilous (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: